N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells

Leukemia

Volumn 18, Issue 3, 2004, Pages 607-615

  Darwiche, N ^a   Hatoum, A ^a   Dbaibo, G ^a   Kadara, H ^a   Nasr, R ^a   Abou Lteif, G ^a   Bazzi, R ^a   Hermine, O ^b   de The H ^c   Bazarbachi, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c CNRS   (France)

Author keywords

HPR; HTLV I; Leukemia; Lymphoma; Retinoids

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CERAMIDE; CYCLIN D1; FENRETINIDE; PROTEASOME; PROTEIN BAX; PROTEIN P21; RETINOIC ACID; RETINOID DERIVATIVE; TAX PROTEIN; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; CASPASE; CDKN1A PROTEIN, HUMAN; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ONCOPROTEIN; PROTEIN BCL 2;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; INHIBITION KINETICS; LYMPHOCYTE ACTIVATION; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN DEGRADATION; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE; CELL CULTURE; CELL DIVISION; DRUG EFFECT; METABOLISM; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; CELL DIVISION; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FENRETINIDE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 1542713521     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403245     Document Type: Article

References (44)

1. De Luca LM. Retinoids and their receptors in differentiation, embryogenesis, and neoplasia. FASEB J 1991; 14: 2924-2933.
2. Lippman SM, Lotan R. Advances in the development of retinoids as chemopreventive agents. Symposium: Diet, natural products and cancer prevention. J Nutr 2000; 130: 479S-482S.
3. Fontana JA, Rishi AK. Classical and novel retinoids: Their targets in cancer therapy. Leukemia 2002; 16: 463-472.
4. Warrell R, cle Thé H, Wang Z, Degos L. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177-189.
5. Cassinat B, Chevret S, Zassadowski F, Balitrand N, Guillemot I, Menot ML et al. In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: A novel indicator of poor patient outcome. Blood 2001; 98: 2862-2864.
6. Dawson MI. Zhang X, Hobbs PD, Jong L In: Livrea MA (ed). Vitamin A and Retinoids: An Update of Biological Aspects and Clinical Applications: Synthetic Retinoids and Their Usefulness in Biology and Medicine## Basel: Birkhauser, Verlag, 2000, pp. 161-196.
7. Delia D, Aiellom A, Lombardim L, Giuseppem P, Pelicci G, Grignani G et al. N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 1993; 53: 6036-6041.
8. Wu JM, DiPietrantonio AM, Hsieh TC. Mechanism of fenretinide (HPR)-induced cell death. Apoptosis 2001; 6: 377-388.
9. Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Moglia D et al. Five-year administration of fenretinide: Pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993; 11: 2036-2042.
10. De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B et al. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 2002; 86: 24-27.
11. Singletary SE, Atkinson EN, Hoque A, Sneige N, Sahin AA, Fritsche HA et al. Phase II clinical trial of N-(4-hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. Clin Cancer Res 2002; 8: 2835-2842.
12. Bazarbachi A, Hermine O. Treatment of adult T-cell leukaemia/lymphoma: Current strategy and future perspectives. Virus Res 2001; 78: 79-92.
13. Hermine OD, Bouscary A, Gessain A, Turlure P, Leblond V, Franck N et al. Brief report: Treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995; 332: 1749-1751.
14. Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated ault T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 1: 186-190.
15. Hermine O, Allard I, Lévy V, Arnulf B, Gessain A, Bazarbachi A. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J 2002; 3: 276-282.
16. Bazarbachi A, El-Sabban ME, Nasr R, Hermine O, de The H. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999; 93: 278-283.
17. El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000; 96: 2849-2855.
18. Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y, Bex F et al. Arsenic/interferon specifically reverses two distinct gene networks critical for the survival of HTLV-I infected leukemic cells. Blood 2003; 101: 4576-4582.
19. Darwiche N, El-Sabban M, Bazzi R, Nasr R, Al-Hashimi S, Hermine O et al. Retinoic acid dramatically enhances the arsenic trioxide induced cell cycle arrest and apoptosis in retinoic acid receptor α-positive Human T cell leukemiavirus type-I transformed cells. Hematol J 2001; 2: 12 7-135.
20. Miyatake JI, Maeda Y. Inhibition of proliferation and CD25 down-regulation by retinoic acid in human adult T cell leukemia. Leukemia 1997; 11: 401-407.
21. Chan LN, Zhang S, Shao J, Waikel R, Thompson EA, Chan TS. N-(4-hydroxyphenyl)retinamide induces apoptosis in T lymphoma and T lymphoblastoid leukemia cells. Leuk Lymphoma 1997; 25: 271-280.
22. O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. Leukemia 2002; 5: 902-910.
23. Hatoum A, El-Sabban ME, Khoury J, Yuspa SH, Darwiche N. Overexpression of retinoic acid receptors alpha and gamma into neoplastic epidermal cells causes retinoic acid-induced growth arrest and apoptosis. Carcinogenesis 2001; 22: 1955-1963.
24. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Phys 1959; 37: 911-917.
25. Bielawska A, Perry DK, Hannun YA. Determination of ceramides and diglycerides by the diglyceride kinase assay. Anal Biochem 2001; 298: 141-150.
26. Zar JH. Biostatistical Analysis. 4th edn New Jersey: Prentice Hall, 1999.
27. Bruno S, Tenca C, Saverino D, Ciccone E, Grossi CE. Apoptosis of squamous cells at different stages of carcinogenesis following 4-HPR treatment. Carcinogenesis 2002; 3: 447-456.
28. Delia D, Aiello A, Formelli F, Fontanella E, Costa A, Miyashita T et al. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl)retinamide and effect of deregulated bcl-2. Blood 1995; 15: 359-367.
29. Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis related genes in human prostate carcinoma cells. Mol Pharmacol 1999; 5: 403-410.
30. Asumendi A, Morales MC, Alvarez A, Arechaga J, Perez-Yarza G. Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl) retinamide-induced apoptosis. Br J Cancer 2002; 12: 1951-1956.
31. Weinberg WC, Denning MF. P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med 2002; 13: 453-464.
32. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1: 639-649.
33. DiPietrantonio AM, Hsieh TC, Juan G, Traganos F, Darzynkiewicz Z, Wu JM. Fenretinide-induced caspase 3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation. Cancer Res 2000; 15: 4331-4335.
34. Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Estrov Z. N-(4-hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukernic and proapoptotic activity in acute lymphoblastic leukemia (ALL). Leuk Res 2003; 3: 259-266.
35. 1/S checkpoint regulators (cyclin D1, cdk4, pRB) and transient modulation of poly(ADP-ribose) polymerase and ceramide level changes by fenretinide N-(4-hydroxyphenyl) retinamide, 4-HPR) in human promyelocytic HL-60 leukemic cells. Int J Cancer 1998; 78: 53-61.
36. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase in ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)retinamide in neuroblastoma cell lines. J Natl Cancer Inst 1999; 9: 1138-1146.
37. Sun SY, Yue P, Lotan R. Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis related genes in human prostate carcinoma cells. Mol Pharmacol 1999; 55: 403-410.
38. Jeang KT. Functional activities of the human T-cell leukemia virus type I Tax oncoprotein: Cellular signaling through NF-kappa B. Cytokine Growth Factor Rev 2001; 12: 207-217.
39. Cereseto A, Diella F, Mulloy JC, Cara A, Michieli P, Grassmann R et al. p53 functional impairment and high p21waf1/cip expression in human T-cell lymphotropic/leukemia virus type 1-transformed T cells. Blood 1996; 88: 1551-1560.
40. de La Fuente C, Santiago F, Chong SY, Deng L, Mayhood T, Fu P et al. Overexpression of p21 (waf1) in human T-cell lymphotropic virus type 1-infected cells and its association with cyclin A/cdk2. J Virol 2 000; 74: 72 70-72 83.
41. Kawata S, Ariumi Y, Shimotohno K. p21(Waf1/Cip1/Sdi1) prevents apoptosis as well as stimulates growth in cells transformed or immortalized by human T-cell leukemia virus type I-encoded tax. J Virol2003; 77: 7291-7299.
42. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d' Etudes des Lymphomes de l'Adulte. Blood 1998; 92: 76-82.
43. Cheng AL, Su IJ, Chen CC, Tien HF. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot study. J Clin Oncol 1994; 12: 1185-1192.
44. Toshima M, Nagai T, Izumi T, Tarumoto T, Imagawa S, Komatsu N et al. All-trans-retinoic acid treatment for chemotherapy-resistant acute adult T-cell leukemia. Int J Hematol 2000; 72: 343-345.